World-class Stem Cell Research Centre for Queenstown

A world-class research and treatment centre that will specialise in using the bodys own blood cells to heal sports injuries and arthritis is planned for Queenstown within the year according to one of the worlds leading experts on Stem Cell Therapy.

Speaking at the New Zealand College of Appearance Medicine Conference in Queenstown yesterday (Thursday August 1), Professor Boyd said Queenstown was at the forefront of Platelet Rich Plasma therapy in the country and was an "obvious choice" to expand into Stem Cell Therapy.

Used in the USA for ten years and Australia for five years, Platelet Rich Plasma (PRP) is already available in New Zealand thanks to Queenstown Regenerative Medicine (QRM) an internationally-linked Queenstown clinic.

Endorsed worldwide by global sports superstars such as Tiger Woods and Kobe Bryant, PRP is a process by which a small amount of blood is taken from the patient and then spun in a centrifuge which automatically produces PRP (blood plasma with a concentrated amount of platelets).

Platelets are the bloods "ambulance, containing over 20 factors important for tissue repair and keeping the body healthy.

The process takes about 15 to 20 minutes and increases the concentration of platelets by up to 500%. The PRP is then injected back into the patients affected area, which reduces inflammation and hence pain, while also stimulating the healing of the tendon or ligament and maybe even cartilage. It can be used in shoulders, knees, ankles, hips, elbows, wrists and much more.

Stem Cell Therapy differs from PRP as it introduces new adult stem cells into damaged tissue in order to treat disease or injury. The stem cells are grown outside the body and then transplanted into the body. It is a lengthier, more involved process, whereas PRP is done purely by injection.

"PRP is thus like the bloods "ambulance" - packed with over 20 factors which not only cause clotting when needed, but can dampen inflammation and reduce pain while also triggering repair processes. Instead of delivering just one signal as common drugs do, they provide a factory of helpers.

"Stem Cell Therapy to heal sports and other injuries has proven to be a great success in clinical trials in the USA and UK, and its our aim to ensure this leading edge therapy is available in New Zealand," said Professor Boyd.

"Our task as researchers is to understand how the body develops in the embryo, is maintained in adults and how it tries to trigger its own repair in disease states.

Read the rest here:
World-class Stem Cell Research Centre for Queenstown

Researchers find home of best stem cells for bone marrow transplants

Aug. 1, 2013 McMaster University researchers have revealed the location of human blood stem cells that may improve bone marrow transplants. The best stem cells are at the ends of the bone.

It is hoped this discovery will lead to lowering the amount of bone marrow needed for a donation while increasing regeneration and lessening rejection in the recipient patients, says principal investigator Mick Bhatia, professor and scientific director of the McMaster Stem Cell and Cancer Research Institute.

In a paper published online today by the journal Cell Stem Cell, his team reports that human stem cells (HSC) residing in the end (trabecular region) of the bones display the highest regenerative ability of the blood and immune system.

"Like the best professional hockey players, our findings indicate blood stem cells are not all equal," said Bhatia. "We now reveal the reason why -- it's not the players themselves, but the effect the arena has on them that makes them the highest scorers."

Bone marrow transplants have been done for more than 50 years and are routine in most hospitals, providing a life saving treatment for cancer and other diseases including leukemia, anemia, and immune disorders.

Bhatia, who also holds a Canada Research Chair in Human Stem Cell Biology, said that cells surrounding the best blood stem cells are critically important, as these "stem cell neighbors" at the end of the bone provide the unique instructions that give these human blood stem cells their superior regenerative abilities.

The research was funded by the Canadian Institutes of Health Research and Ontario Cancer Research Institute.

See the original post here:
Researchers find home of best stem cells for bone marrow transplants

Stem Cells Market Research Report Published by Transparency Market Research

Albany, New York (PRWEB) August 02, 2013

According to a new market report published by Transparency Market Research "Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018.

Related Report : Dental Equipment Market http://www.transparencymarketresearch.com/dental-devices-market.html

The market growth is majorly attributed to therapeutic research activities led by government support worldwide owing to the growing number of patients with chronic diseases across the globe. In addition, rising awareness of regenerative treatment options and growing importance of stem cell banking services are also fostering the growth of the market. Apart from these, development of medical tourism hubs in developing nations such as India and China and in turn migration of patients from developed nations such as the U.S., and Europe for quality treatment at significantly lower prices will also serve the market as a driver especially for the Asian stem cells market.

Related Report : Biosensors Market http://www.transparencymarketresearch.com/biosensors-market.html

Stem cells market will be driven by rising proportion of patients with neurological and other chronic conditions and rising disposable incomes of patients induced by economic growth of Asian regions in the next five years In addition, increasing dependence on stem cells for drug discovery and screening will boost the growth of the market in future. Increased outsourcing of contract research and clinical trials to developing Asian regions will further encourage growth of the stem cells market.

Adult stem cells held majority share of the overall stem cells market in 2011 at over 80%. This is due to less laborious procedure of harvesting, and less probability of contamination during expansion and sub-culture of adult stem cells. However, fewer post-transplant complications and lesser risk of graft vs. host reaction from the recently introduced induced pluripotent stem cells will lead to its rapid inclusion in research activities and help the global induced pluripotent stem cells market to grow at a relatively faster CAGR during the forecast period.

Browse the full report with TOC at http://www.transparencymarketresearch.com/stem-cells-market.html.

Regenerative medicine dominated the stem cells market by applications in 2011, and is expected to maintain its leading position till 2018. Considerable research activities and the resultant developed therapies in neurology will drive the stem cells market in the forecast period.

North America was the market leader of the total stem cells market in 2011 and is expected to maintain its leading position till 2018. North American market is a center for stem cells research owing to greater support offered by federal government, and higher affordability of treatment in the region.

Here is the original post:
Stem Cells Market Research Report Published by Transparency Market Research

Tampa-Based Pulmonary Stem Cell Treatment Clinic Shows Promising Results

Tampa, Florida (PRWEB) August 01, 2013

State-of-the-art pulmonary stem cell treatment provider, Lung Institute (LI), opened in May with the goal of providing those with debilitating lung conditions a better quality of life. That goal is quickly becoming realized.

Since the May opening, LI has treated over 40 patients with a variety of conditions ranging from COPD to ulcerative colitis. In a six week follow up survey, nearly 70% of patients reported positive results.

Considering most of our patients have been told by doctors that they have no further course of treatment, these numbers are amazing, said Jimmy St. Louis, CEO of Lung Institute. And this is just the beginning. With more and more patients reaching the six week post treatment mark, we are excited to see these numbers grow.

People from all across the nation are taking notice of Lung Institutes innovative procedures utilizing regenerative medicine. Their highly trained physicians have already touched the lives of patients from across the nation, and the world. Collectively, Lung Institutes patients have traveled over 33,750 miles for treatment, and have come from places as far away as Brazil, South Africa, the United Kingdom, and the Philippines.

About Lung Institute: At Lung Institute (LI), we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. At our state-of-the-art facilities our personalized treatment protocols were established with the highest concern for patient safety and quality of care. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care.

See the original post:
Tampa-Based Pulmonary Stem Cell Treatment Clinic Shows Promising Results

World-class Stem Cell Research, Therapy for Queenstown

Media release from Queenstown Regenerative Medicine August 2 2013

World-class Stem Cell Research and Therapy Centre for Queenstown

A world-class research and treatment centre that will specialise in using the bodys own blood cells to heal sports injuries and arthritis is planned for Queenstown within the year according to one of the worlds leading experts on Stem Cell Therapy.

Speaking at the New Zealand College of Appearance Medicine Conference in Queenstown yesterday (Thursday August 1), Professor Boyd said Queenstown was at the forefront of Platelet Rich Plasma therapy in the country and was an obvious choice to expand into Stem Cell Therapy.

Used in the USA for ten years and Australia for five years, Platelet Rich Plasma (PRP) is already available in New Zealand thanks to Queenstown Regenerative Medicine (QRM) an internationally-linked Queenstown clinic.

Endorsed worldwide by global sports superstars such as Tiger Woods and Kobe Bryant, PRP is a process by which a small amount of blood is taken from the patient and then spun in a centrifuge which automatically produces PRP (blood plasma with a concentrated amount of platelets).

Platelets are the bloods ambulance, containing over 20 factors important for tissue repair and keeping the body healthy.

The process takes about 15 to 20 minutes and increases the concentration of platelets by up to 500%. The PRP is then injected back into the patients affected area, which reduces inflammation and hence pain, while also stimulating the healing of the tendon or ligament and maybe even cartilage. It can be used in shoulders, knees, ankles, hips, elbows, wrists and much more.

Stem Cell Therapy differs from PRP as it introduces new adult stem cells into damaged tissue in order to treat disease or injury. The stem cells are grown outside the body and then transplanted into the body. It is a lengthier, more involved process, whereas PRP is done purely by injection.

PRP is thus like the bloods ambulance packed with over 20 factors which not only cause clotting when needed, but can dampen inflammation and reduce pain while also triggering repair processes. Instead of delivering just one signal as common drugs do, they provide a factory of helpers.

Go here to read the rest:
World-class Stem Cell Research, Therapy for Queenstown

World-class stem cell centre for Queenstown

A world-class research and treatment centre that will specialise in using the bodys own blood cells to heal sports injuries and arthritis is planned for Queenstown within the year according to one of the worlds leading experts on Stem Cell Therapy.

Speaking at the New Zealand College of Appearance Medicine Conference in Queenstown yesterday (Thursday August 1), Professor Boyd said Queenstown was at the forefront of Platelet Rich Plasma therapy in the country and was an "obvious choice" to expand into Stem Cell Therapy.

Used in the USA for ten years and Australia for five years, Platelet Rich Plasma (PRP) is already available in New Zealand thanks to Queenstown Regenerative Medicine (QRM) an internationally-linked Queenstown clinic.

Endorsed worldwide by global sports superstars such as Tiger Woods and Kobe Bryant, PRP is a process by which a small amount of blood is taken from the patient and then spun in a centrifuge which automatically produces PRP (blood plasma with a concentrated amount of platelets).

Platelets are the bloods "ambulance, containing over 20 factors important for tissue repair and keeping the body healthy.

The process takes about 15 to 20 minutes and increases the concentration of platelets by up to 500%. The PRP is then injected back into the patients affected area, which reduces inflammation and hence pain, while also stimulating the healing of the tendon or ligament and maybe even cartilage. It can be used in shoulders, knees, ankles, hips, elbows, wrists and much more.

Stem Cell Therapy differs from PRP as it introduces new adult stem cells into damaged tissue in order to treat disease or injury. The stem cells are grown outside the body and then transplanted into the body. It is a lengthier, more involved process, whereas PRP is done purely by injection.

"PRP is thus like the bloods "ambulance" - packed with over 20 factors which not only cause clotting when needed, but can dampen inflammation and reduce pain while also triggering repair processes. Instead of delivering just one signal as common drugs do, they provide a factory of helpers.

"Stem Cell Therapy to heal sports and other injuries has proven to be a great success in clinical trials in the USA and UK, and its our aim to ensure this leading edge therapy is available in New Zealand," said Professor Boyd.

"Our task as researchers is to understand how the body develops in the embryo, is maintained in adults and how it tries to trigger its own repair in disease states.

Link:
World-class stem cell centre for Queenstown

Press Release

California Stem Cell Inc.Posted on:31 Jul 13

California Stem Cell Inc. (CSC) has announced the completion of an internal study demonstrating that the companys proprietary immunotherapy manufacturing process can be applied to multiple cancer types. Originally developed for late stage metastatic melanoma the platform tissue culture technology has also been shown to work with tumor tissues from hepatocellular carcinoma ovarian cancer glioblastoma multiforme and other solid tumor cancers.

The unique principle supporting CSCs cancer immunotherapeutic approach is purification of tumor stem cells isolated from a patients own tumor tissue to use as an antigenic source. While prior companies processes typically took months and often yielded unreliable or unusable materials CSC has standardized its platform technology for reproducibility resulting in optimized high cell yields and efficient and scalable manufacturing.

The companys proprietary stem cell culturing technologies performed under cGMP conditions have resulted in a consistent production time of less than 8 weeks with a 100% success rate in generating lines with potential applicability to a broad range of cancer types.

Such significant improvements in the manufacturing time and success rate are critical when working with late stage cancers that typically have a short window for treatment said Gabriel Nistor M.D. CSC Vice President of Research and Development. The improvements allowed us to test our proprietary manufacturing methods on a broader range of devastating cancer types with encouraging results.

CSC recently submitted a Phase III protocol to the U.S. Food and Drug Administration to explore efficacy of its cancer stem cell-based treatment for recurrent stage III and stage IV melanoma. The company is also completing a Phase I clinical study in liver cancer and preparing to submit a Phase II clinical study in ovarian cancer.

About California Stem Cell

California Stem Cell Inc. (CSC) is an Irvine CA-based company focused on the development of stem cell-based therapies for metastatic cancers spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS or Lou Gehrigs Disease).

CSC has proprietary methods to generate human stem cell lines expand them to clinically and commercially useful numbers and differentiate them at extremely high purity using fully-defined proprietary media and cGMP processes.

Follow us on Twitter: http://twitter.com/castemcell

Read more here:
Press Release

Research and Markets: The Mesenchymal Stem Cells (MSC) Product Market 2013 – The fastest growing area of stem cell …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/mqlqdz/mesenchymal_stem) has announced the addition of the "The Mesenchymal Stem Cells (MSC) Product Market 2013" report to their offering.

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

Trend analysis of grant activity, scientific publication rates, and patent applications trends reveal that global research activity involving mesenchymal stem cells (MSCs) increased 112% from 2009 to 2010, and 116% from 2010 to 2011. Of most interest is that this rate of growth accelerated throughout 2011, making mesenchymal stem cells the fastest growing area of stem cell research.

Because mesenchymal stem cell researchers represent a rapidly growing, well-funded research community, this report presents strategies for research supply companies to use to develop high-demand products for this community. A key element of this report is a survey of mesenchymal stem cell (MSC) researchers.

This survey reveals critical findings that include:

- Preferred Tissue Source for MSCs

- Preferred Species Source for MSCs

- MSC Product Preferences

Link:
Research and Markets: The Mesenchymal Stem Cells (MSC) Product Market 2013 - The fastest growing area of stem cell ...